| scholarly article | Q13442814 |
| P50 | author | Vishnu V B Reddy | Q39995100 |
| Kurt R. Zinn | Q39995144 | ||
| Gene P. Siegal | Q93491237 | ||
| P2093 | author name string | Diptiman Chanda | |
| Selvarangan Ponnazhagan | |||
| Tatyana Isayeva | |||
| Sanjay Kumar | |||
| April A Szafran | |||
| P2860 | cites work | Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 |
| Key roles of the OPG-RANK-RANKL system in bone oncology | Q28287394 | ||
| Cancer statistics, 2007 | Q29547293 | ||
| Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy | Q30437441 | ||
| Gene therapy with human osteoprotegerin decreases callus remodeling with limited effects on biomechanical properties | Q33223536 | ||
| Mechanisms of bone metastasis | Q33977526 | ||
| Adeno-associated virus vectors: potential applications for cancer gene therapy | Q36165834 | ||
| Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. | Q36366450 | ||
| Role of osteoprotegerin (OPG) in cancer | Q36389753 | ||
| The RANK/RANKL/OPG triad in cancer-induced bone diseases | Q36688664 | ||
| The bone microenvironment in metastasis; what is special about bone? | Q37028803 | ||
| Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone | Q39946634 | ||
| Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. | Q40210622 | ||
| Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. | Q40296427 | ||
| Regulation of cancer cell migration and bone metastasis by RANKL. | Q40298349 | ||
| Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival? | Q40374890 | ||
| The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. | Q40432075 | ||
| A helper virus-free packaging system for recombinant adeno-associated virus vectors | Q40916579 | ||
| Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells | Q41128137 | ||
| A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases | Q44291815 | ||
| Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption | Q44725393 | ||
| Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model | Q45730626 | ||
| Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield | Q45747699 | ||
| Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model | Q45868850 | ||
| Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption | Q45869910 | ||
| Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice | Q45874107 | ||
| Osteoprotegerin in prostate cancer bone metastasis. | Q51531894 | ||
| Breast cancer cells induce osteoblast apoptosis: a possible contributor to bone degradation. | Q51719076 | ||
| The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. | Q53621774 | ||
| P433 | issue | 5 | |
| P921 | main subject | gene therapy | Q213901 |
| P304 | page(s) | 871-878 | |
| P577 | publication date | 2008-03-18 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis | |
| P478 | volume | 16 |
| Q37148669 | 89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors |
| Q39030024 | Colony-stimulating factor 1 potentiates lung cancer bone metastasis |
| Q36240183 | Comparative Effects of Ibandronate and Paclitaxel on Immunocompetent Bone Metastasis Model. |
| Q37658767 | Emerging therapeutic targets in breast cancer bone metastasis |
| Q36571484 | Importance of osteoprotegrin and receptor activator of nuclear factor κB in breast cancer response to hepatocyte growth factor and the bone microenvironment in vitro |
| Q34473019 | Musculoskeletal molecular imaging: a comprehensive overview |
| Q36296474 | Oncostatin m promotes mammary tumor metastasis to bone and osteolytic bone degradation |
| Q34998448 | Osteoprotegerin expression in triple-negative breast cancer cells promotes metastasis |
| Q26748804 | Osteoprotegerin rich tumor microenvironment: implications in breast cancer |
| Q54391573 | Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties. |
| Q37199218 | RANK, RANKL and osteoprotegerin in bone biology and disease. |
| Q60917149 | RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives |
| Q57801311 | Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort |
| Q34147824 | Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis |
Search more.